Ask AI
ProCE Banner Activity

Beamion LUNG-1: Patient-Reported Outcomes With Zongertinib for Previously Treated Advanced HER2-Mutant NSCLC

Conference Coverage
Slideset

Patient-reported outcomes in Beamion LUNG-1 show that pretreated patients with advanced HER2-mutant NSCLC experience improvement in disease-related symptoms and physical functioning with zongertinib.

Released: June 05, 2025

Expiration: December 04, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, and PharmaMar.

AstraZeneca

Boehringer Ingelheim Pharmaceuticals, Inc.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

PharmaMar